Optic neuritis (ON) is a self-limiting condition caused by inflammation-driven demyelination process affecting the optic nerve. Main clinical features are sudden, unilateral worsening of visual acuity, colour vision disturbance, visual field defects and motion-induced ocular pain. Spontaneous recovery appears usually within up to 8 weeks. It is a frequent initial manifestation of multiple sclerosis. Treatment of optic neuritis remains controversial, although many clinical trials have been conducted to establish firm therapeutic guidelines. The most relevant clinical trial is the Optic Neuritis Treatment Trial (ONTT), proving three days’ intravenous methylprednisolone therapy is not able to change the long-term prognosis, however improving visual recovery, what became a therapeutic option in monocular patients, patients with significant visual field loss, as well as those with professional requirements of fast visual recovery. The ONTT showed that 15-year risk of developing multiple sclerosis was 50 % regardless of the treatment regimen. Oral corticosteroids are recommended for treatment of acute optic neuritis.
Optic neuritis, multiple sclerosis, treatment, corticosteroids, Optic Neuritis Treatment Trial, ONTT
The authors have no conflicts of interest to declare.
Andrzej Grzybowski, Department of Ophthalmology, Poznan City Hospital, 3 Szwajcarska St, 361-285 Poznań,Poland. E: firstname.lastname@example.org
Share this Article
Related Content In Neuro-ophthalmology
Pharmacologic Mydriasis and Cycloplegia: A Review of Novel Delivery Devices
touchREVIEWS in Ophthalmology. 2023;17(2):1–3:Online ahead of journal publication
Mydriasis physiology Mydriasis refers to physiologic or pharmacologic pupillary dilation. Physiologic pupillary dilation occurs naturally as a response to low light and viewing objects in the distance. This process is mediated by both the iris sphincter and the iris dilator muscles, the latter of which contracts in response to sympathetic stimulation and relaxes in response to […]
Current and Emerging Therapies for Leber Hereditary Optic Neuropathy
touchREVIEWS in Ophthalmology. 2023;17(1):21–24 DOI: https://doi.org/10.17925/USOR.2023.17.1.21
Leber hereditary optic neuropathy (LHON) is a mitochondrially inherited optic nerve disease characterized by bilateral (sequential or simultaneous), subacute, painless central vision loss.1 LHON was first described in 1871 by the German ophthalmologist Theodor Leber.2 However, it was not until 1988 that the mitochondrial mutation was discovered by Wallace et al.3 LHON is the most common hereditary mitochondrial optic neuropathy. Several primary mitochondrial […]
Nonorganic Vision Loss
European Ophthalmic Review. 2020;14(1):26–33 DOI: https://doi.org/10.17925/EOR.2020.14.1.26
Nonorganic vision loss (NOVL) or functional vision loss (FVL) is the presence of abnormal vision, or visual fields, without an organic pathology, despite a thorough and comprehensive evaluation. The symptoms will be inconsistent with the results of an objective examination.1–3 In some cases, vision loss is intentionally feigned, while in others it occurs under unconscious conditions. […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!